Screener
Perrigo Company PRGO Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Infant Formula | $100.9M+23.0% | $89.7M+2.2% | —— | —— | $82M— | |
| Self Care | $576.6M-3.7% | $543.3M-11.6% | —— | —— | $598.6M— | |
| Specialty Care | $226.6M-2.8% | $207M+4.0% | —— | —— | $233.1M— | |
| Net Sales by Product | ||||||
| Digestive Health | $115.7M-3.4% | $96.6M-14.4% | $134M-7.7% | $116.1M-5.2% | $119.8M-10.9% | |
| Healthy Lifestyle | $157.8M+2.0% | $142.7M-9.1% | $146.2M+7.4% | $130.3M-2.8% | $154.7M+22.2% | |
| Pain & Sleep | $124.6M-12.7% | $106.6M-17.8% | —— | —— | $142.8M— | |
| Skin Health | $161.8M-5.0% | $151.9M+1.5% | —— | —— | $170.3M— | |
| Upper Respiratory | $178.4M-1.6% | $197.4M-8.1% | $217.8M+5.5% | $209.8M+1.4% | $181.3M+7.0% | |
| Women's Health | $64.8M+3.3% | $55.1M+11.3% | $59.9M+18.1% | $48.9M-2.6% | $62.7M+16.8% | |
| Net Sales by Geography | ||||||
| All other countries | $24.7M+4.2% | $23.4M+4.9% | $26.6M-1.5% | $24M-27.9% | $23.7M-19.1% | |
| Europe | $371.7M-11.9% | $391.4M-5.1% | $398.4M+5.1% | $384M-3.3% | $421.7M+3.3% | |
| Ireland | $7.7M-21.4% | $4.1M-62.7% | $12.7M-0.8% | $8.6M-22.5% | $9.8M-14.0% | |
| U.S. | $626.4M+2.5% | $554.4M-9.0% | $684.6M-6.5% | $635.3M-3.3% | $610.9M-2.7% |
FAQ
- How does Perrigo Company break its business down?
- Perrigo Company (PRGO) reports net sales by business across 3 parts — Infant Formula, Self Care and Specialty Care. Each is extracted from the segment footnotes and tracked over time.
- Where does Perrigo Company's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Perrigo Company's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
